Key result
Paclitaxel- and sirolimus-eluting stents were associated with coronary vasoconstriction, whereas biolimus A9, zotarolimus, and bare-metal stents maintained normal vasomotion.
Why the study?
Do different drug-eluting stents affect endothelium-dependent coronary vasomotion compared to bare-metal stents in patients with implanted coronary stents?
Cohort (n=83)
Do different drug-eluting stents affect endothelium-dependent coronary vasomotion compared to bare-metal stents in patients with implanted coronary stents?
First-generation drug-eluting stents (paclitaxel, sirolimus) are associated with endothelial dysfunction, whereas newer generation stents (biolimus A9, zotarolimus) preserve endothelial vasomotor response similar to bare-metal stents.
Answers are grounded in this paper and cite their sources.
First-generation DES may impair vasomotion; leaves open effects on clinical outcomes versus newer DES or BMS.
BACKGROUND: There is evidence that endothelial coverage of drug-eluting stents might be delayed or absent, a risk factor for late thrombotic events. We studied the effects of different drug-polymer-device iterations on endothelium-dependent coronary vasomotion. Systemic markers of endothelial inflammation were correlated with coronary vasomotor changes. METHODS AND RESULTS: Patients with paclitaxel-eluting stents (n=11), sirolimus-eluting stents (n=21), biolimus A9-eluting stents (n=28), zotarolimus-eluting stents (n=10), and bare-metal stents (n=13) were studied 10, 9, 9, 9, and 12 months after implantation, respectively. Endothelium-dependent coronary vasomotion was tested proximally and distally to the stent and at a reference vessel segment during atrial pacing at increasing heart rates by quantitative coronary angiography. Indexes of platelet-monocyte binding and other biomarkers were studied in a subgroup of 19 patients. The baseline characteristics and hemodynamics of the patients in the different stent groups were comparable. Significant differences were observed across the 5 stent groups, concerning the vasomotion of segments proximal (P=0.006) and distal (P=0.003) to the stent. Normal vasomotion (vasodilatation) was maintained in the biolimus A9-eluting stent, zotarolimus-eluting stent, and bare-metal stent groups, whereas vasoconstriction was observed in the sirolimus-eluting stent and paclitaxel-eluting stent groups. Platelet-monocyte binding in whole blood showed a significant inverse correlation with vasomotion in reference but not in segments adjacent to the stent (r=-0.57; P=0.01). CONCLUSIONS: Paclitaxel-eluting stents and sirolimus-eluting stents seem to cause endothelial dysfunction of the implanted vessel, whereas biolimus A9-eluting stents and zotarolimus-eluting stents behave more closely to bare-metal stents, with preserved endothelial vasomotor response. Coronary vasoconstriction was not associated with detectable systemic endothelial activation.
No takes yet. Share an insight, caveat, or question.
Hamilos et al. (2008) conducted a cohort in Coronary artery disease with implanted stents (n=83). Drug-eluting stents (paclitaxel, sirolimus, biolimus A9, zotarolimus) vs. Bare-metal stents was evaluated on Endothelium-dependent coronary vasomotion of segments proximal and distal to the stent (p=0.006 (proximal), 0.003 (distal)). Paclitaxel- and sirolimus-eluting stents were associated with coronary vasoconstriction, whereas biolimus A9, zotarolimus, and bare-metal stents maintained normal vasomotion.
Synapse has enriched 10 related papers. Consider them for comparative context: